Press Room


    Press Release - April 30, 2012

    Sernova Announces Appointments to Board of Directors

    LONDON, ONTARIO - (Marketwire - April 30, 2012) - Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE: SVA - News) today announced that at the annual general meeting held April 19, 2012, Bruce Weber and James Parsons were elected to the Corporation's Board of Directors.

    "The appointment of Mr. Weber and Mr. Parsons strengthens Sernova's Board from a perspective in the international clinical, regulatory and corporate finance arenas," said Dr. George Adams, Chairman of the Board of Directors of Sernova. "With Sernova's upcoming launch of its first in man Canadian clinical trial of the Cell Pouch(TM), the company is strategically focused on clinical validations and partnerships to advance its products. The board now has seasoned Directors with operational and transactional experience to properly govern and guide the Company."

    In his distinguished career, Mr. Weber is currently Vice President, Clinical, Regulatory and Quality Assurance at Innovia LLC, since 2004. Prior to this appointment, Mr. Weber held a number of senior management positions including Vice President of Product Assurance at Syntheon LLC from 1998 to 2004, Vice President, Product Assurance at Corvita Corporation from 1989 to 1998, and Corporate Quality Assurance Manager at Organon Teknika from 1987 to 1988. He also held positions as Director of Manufacturing at BioNexus, Senior Regulatory Affairs Associate at Cordis Corporation, Production Manager at C.R. Bard, Inc. and Quality Control Manager at Cordis Dow Corporation.

    Mr. Parsons is currently Vice President Finance and Corporate Secretary at Diamedica, Inc. since 2010 and also is Chief Financial Officer of Stem Cell Therapeutics Corp. since August 2011. Prior to these positions Mr. Parsons was Chief Financial Officer and Corporate Secretary of Amorfix Life Sciences, Ltd. from 2005 to 2010. Mr. Parsons also holds senior positions with a number of biotechnology companies and advises a number of early-stage companies within the industry. Mr. Parsons has over twenty years of experience working with Board of Directors and Audit Committees and has extensive experience in establishing and developing committee policies, mandates and governance processes. Mr. Parsons has secured approximately $100M of financing during his career and has advised and assisted on over $200M of product out-licensing, research agreements and in-licensing deals.

    In connection with the appointment of Mr. Weber and Mr. Parsons, they were each granted 250,000 options on April 19, 2012 to purchase shares at an exercise price of $0.18 for a period of 5 years in accordance with the provisions of the Sernova stock option plan.

    About Sernova

    Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using the novel Cell Pouch System(TM) and its patented Sertolin(TM) cell technology.

    For further information contact:

    Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939

    Tony Russo, Ph.D. Russo Partners, LLC Tel: (212) 845-4251

    Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward- looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward- looking statements whether as a result of new information, future events or otherwise.

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News